Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy

被引：70

作者：

Queirolo, Paola ^{[1
]}

Boutros, Andrea ^{[1
]}

Tanda, Enrica ^{[1
]}

Spagnolo, Francesco ^{[1
]}

Quaglino, Pietro ^{[2
]}

机构：

[1] IRCCS Osped Policlin San Martino, Skin Canc Unit, Genoa, Italy

[2] Univ Turin, Med Sch, Dept Med Sci, Dermatol Clin, Turin, Italy

来源：

SEMINARS IN CANCER BIOLOGY | 2019年 / 59卷

关键词：

Melanoma; Immunotherapy; Immune-checkpoint inhibitors; CTLA-4; PD-1; Biomarker; CUTANEOUS ADVERSE EVENTS; OPEN-LABEL; COMBINED NIVOLUMAB; TUMOR RESPONSE; CHECKMATE; 037; DOUBLE-BLIND; IPILIMUMAB; PEMBROLIZUMAB; SURVIVAL; PHASE-3;

D O I：

10.1016/j.semcancer.2019.08.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.

引用

页码：290 / 297

页数：8

共 50 条

[41] Fucose signatures in peripheral blood glycoproteins are associated with reduced clinical benefit of immune-checkpoint inhibitors in metastatic melanoma
Pickering, Chad
Chu, Chih-Wei
Aval, Tomislav C. .
Rice, Rachel
Frederick, Dennie
Boland, Genevieve
Serie, Daniel
Lindpaintner, Klaus
Schwarz, Flavio
GLYCOBIOLOGY, 2022, 32 (11) : 1002 - 1002
[42] Treatment patterns of checkpoint inhibitors in metastatic melanoma
Machado, Marina A. A.
Moura, Cristiano S.
Curtis, Jeffrey R.
Hudson, Marie
Bernatsky, Sasha
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 395 - 396
[43] Cancer immunotherapy beyond immune checkpoint inhibitors
Marin-Acevedo, Julian A.
Soyano, Aixa E.
Dholaria, Bhagirathbhai
Knutson, Keith L.
Lou, Yanyan
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[44] Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin-Acevedo
Aixa E. Soyano
Bhagirathbhai Dholaria
Keith L. Knutson
Yanyan Lou
Journal of Hematology & Oncology, 11
[45] New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
Ciccarese, C.
Alfieri, S.
Santoni, M.
Santini, D.
Brunelli, M.
Bergamini, C.
Licitra, L.
Montironi, R.
Tortora, G.
Massari, F.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (01) : 57 - 75
[46] Beyond current immune-checkpoint inhibitors
Torigoe, Toshihiko
Chung, Junho
CANCER SCIENCE, 2018, 109 : 622 - 622
[47] Immune-checkpoint inhibitors in pituitary malignancies
Di Nunno, Vincenzo
Franceschi, Enrico
Tosoni, Alicia
Gatto, Lidia
Maggio, Ilaria
Lodi, Raffaele
Bartolini, Stefania
Brandes, Alba A.
ANTI-CANCER DRUGS, 2022, 33 (01) : E28 - E35
[48] Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Brahmer, Julie R.
Pardoll, Drew M.
CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) : 85 - 91
[49] Radiation in combination with immune-checkpoint inhibitors
Mayor, Susan
LANCET ONCOLOGY, 2015, 16 (04): : E162 - E162
[50] Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Karasarides, Maria
Cogdill, Alexandria P.
Robbins, Paul B.
Bowden, Michaela
Burton, Elizabeth M.
Butterfield, Lisa H.
Cesano, Alessandra
Hammer, Christian
Haymaker, Cara L.
Horak, Christine E.
McGee, Heather M.
Monette, Anne
Rudqvist, Nils-Petter
Spencer, Christine N.
Sweis, Randy F.
Vincent, Benjamin G.
Wennerberg, Erik
Yuan, Jianda
Zappasodi, Roberta
Lucey, Vanessa M. Hubbard
Wells, Daniel K.
LaVallee, Theresa
CANCER IMMUNOLOGY RESEARCH, 2022, 10 (04) : 372 - 383

← 1 2 3 4 5 →